Collegium Pharmaceutical (COLL) Stock Forecast, Price Target & Predictions
COLL Stock Forecast
Collegium Pharmaceutical stock forecast is as follows: an average price target of $42.33 (represents a 42.53% upside from COLL’s last price of $29.70) and a rating consensus of 'Buy', based on 8 wall street analysts offering a 1-year stock forecast.
COLL Price Target
The average price target for Collegium Pharmaceutical (COLL) is $42.33 based on 1-year price targets from 8 Wall Street analysts in the past 3 months, with a price target range of $50.00 to $37.00. This represents a potential 42.53% upside from COLL's last price of $29.70.
COLL Analyst Ratings
According to 8 Wall Street analysts, Collegium Pharmaceutical's rating consensus is 'Buy'. The analyst rating breakdown for COLL stock is 0 'Strong Buy' (0.00%), 5 'Buy' (62.50%), 2 'Hold' (25.00%), 1 'Sell' (12.50%), and 0 'Strong Sell' (0.00%).
Collegium Pharmaceutical Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 11, 2024 | Glen Santangelo | Jefferies | $40.00 | $32.18 | 24.30% | 34.68% |
| Sep 04, 2024 | Oren Livnat | H.C. Wainwright | $50.00 | $38.65 | 29.37% | 68.35% |
| Aug 09, 2024 | David Amsellem | Piper Sandler | $37.00 | $34.63 | 6.86% | 24.58% |
| Jul 30, 2024 | Oren Livnat | H.C. Wainwright | $47.00 | $38.60 | 21.76% | 58.25% |
| Jun 07, 2024 | Glen Santangelo | Jefferies | $44.00 | $31.36 | 40.31% | 48.15% |
| May 10, 2024 | David Amsellem | Piper Sandler | $39.00 | $33.11 | 17.79% | 31.31% |
| Jan 05, 2023 | Needham | $35.00 | $26.98 | 29.73% | 17.85% |
The latest Collegium Pharmaceutical stock forecast, released on Nov 11, 2024 by Glen Santangelo from Jefferies, set a price target of $40.00, which represents a 24.30% increase from the stock price at the time of the forecast ($32.18), and a 34.68% increase from COLL last price ($29.70).
Collegium Pharmaceutical Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 6 |
| Avg Price Target | - | $40.00 | $42.83 |
| Last Closing Price | $29.70 | $29.70 | $29.70 |
| Upside/Downside | -100.00% | 34.68% | 44.21% |
In the current month, the average price target of Collegium Pharmaceutical stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Collegium Pharmaceutical's last price of $29.70. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Nov 11, 2024 | Jefferies | Buy | Buy | Hold |
| Oct 11, 2024 | Piper Sandler | Neutral | Neutral | Hold |
| Sep 05, 2024 | Morgan Stanley | Overweight | Overweight | Hold |
| Sep 05, 2024 | Susquehanna | Negative | Downgrade | |
| Sep 05, 2024 | BMO Capital | Market Perform | Downgrade | |
| Sep 05, 2024 | Piper Sandler | Buy | Buy | Hold |
| Sep 05, 2024 | Needham | Buy | Buy | Hold |
| Sep 04, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 09, 2024 | Piper Sandler | Neutral | Neutral | Hold |
| Jul 30, 2024 | H.C. Wainwright | Buy | Upgrade | |
| Jun 07, 2024 | Jefferies | Underperform | Buy | Upgrade |
| May 10, 2024 | Sandler O'Neill | Buy | Buy | Hold |
| May 10, 2024 | Sandler O'Neil | Underperform | Underperform | Hold |
| May 10, 2024 | Needham | Underperform | Hold | Downgrade |
| May 10, 2024 | Piper Sandler | Buy | Neutral | Downgrade |
| Feb 23, 2024 | Needham | Underperform | Underperform | Hold |
| Feb 23, 2024 | Piper Sandler | Buy | Buy | Hold |
| Feb 02, 2024 | Needham | Buy | Buy | Hold |
| Feb 02, 2024 | Jefferies | Underperform | Underperform | Hold |
| Aug 25, 2023 | Needham | Buy | Buy | Hold |
| Jan 05, 2023 | Needham | Buy | Buy | Hold |
| Feb 22, 2022 | Piper Sandler | Overweight | Overweight | Hold |
Collegium Pharmaceutical's last stock rating was published by Jefferies on Nov 11, 2024. The company gave COLL a "Buy" rating, the same as its previous rate.
Collegium Pharmaceutical Financial Forecast
Collegium Pharmaceutical Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $136.71M | $135.55M | $144.77M | $129.62M | $127.01M | $123.55M | $83.75M | $27.36M | $78.84M | $82.94M | $87.72M | $76.27M | $79.18M | $78.06M | $76.51M | $74.20M | $72.94M | $75.04M | $74.52M | $63.75M | $2.17M |
| Avg Forecast | $195.07M | $190.48M | $185.06M | $181.43M | $179.48M | $155.65M | $143.94M | $146.94M | $147.86M | $137.27M | $138.46M | $138.36M | $125.22M | $124.38M | $121.13M | $78.67M | $81.53M | $85.06M | $84.61M | $81.78M | $77.43M | $77.45M | $74.42M | $76.65M | $73.37M | $74.42M | $75.85M | $70.30M | $54.80M | $2.69M |
| High Forecast | $197.44M | $192.80M | $187.31M | $183.11M | $182.06M | $156.78M | $143.94M | $147.24M | $148.74M | $141.36M | $140.14M | $140.04M | $126.74M | $124.38M | $121.13M | $78.67M | $81.53M | $85.06M | $84.61M | $81.78M | $77.43M | $77.45M | $74.42M | $76.65M | $73.37M | $74.42M | $75.85M | $70.30M | $65.76M | $3.23M |
| Low Forecast | $192.96M | $188.42M | $183.06M | $179.74M | $176.82M | $154.52M | $143.94M | $146.63M | $146.15M | $130.89M | $136.96M | $136.86M | $123.86M | $124.38M | $121.13M | $78.67M | $81.53M | $85.06M | $84.61M | $81.78M | $77.43M | $77.45M | $74.42M | $76.65M | $73.37M | $74.42M | $75.85M | $70.30M | $43.84M | $2.16M |
| # Analysts | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 1 | 3 | 6 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 12 | 15 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.00% | 0.98% | 1.05% | 1.04% | 1.02% | 1.02% | 1.06% | 0.34% | 0.93% | 0.98% | 1.07% | 0.99% | 1.02% | 1.05% | 1.00% | 1.01% | 0.98% | 0.99% | 1.06% | 1.16% | 0.81% |
Collegium Pharmaceutical's average Quarter revenue forecast for Dec 23 based on 3 analysts is $147.86M, with a low forecast of $146.15M, and a high forecast of $148.74M. COLL's average Quarter revenue forecast represents a 8.16% increase compared to the company's last Quarter revenue of $136.71M (Sep 23).
Collegium Pharmaceutical EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 1 | 3 | 6 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 12 | 15 |
| EBITDA | - | - | - | - | - | - | - | - | - | $45.01M | $35.63M | $65.66M | $12.78M | $58.52M | $49.27M | $9.63M | $-29.54M | $31.40M | $33.63M | $38.43M | $32.08M | $36.62M | $33.55M | $15.77M | $1.89M | $-2.01M | $-617.00K | $-5.59M | $17.06M | $-22.97M |
| Avg Forecast | $61.68M | $60.23M | $58.52M | $57.37M | $56.75M | $49.22M | $45.51M | $15.84M | $46.76M | $43.41M | $43.78M | $14.40M | $-47.92M | $21.11M | $20.55M | $13.09M | $13.83M | $14.43M | $14.36M | $24.34M | $13.14M | $13.14M | $12.63M | $28.00M | $12.45M | $12.63M | $12.87M | $-4.43M | $14.27M | $-27.19M |
| High Forecast | $62.43M | $60.96M | $59.23M | $57.90M | $57.57M | $49.58M | $45.51M | $19.01M | $47.03M | $44.70M | $44.31M | $17.28M | $-38.33M | $21.11M | $20.55M | $15.71M | $13.83M | $14.43M | $14.36M | $29.21M | $13.14M | $13.14M | $12.63M | $33.59M | $12.45M | $12.63M | $12.87M | $-3.54M | $17.13M | $-21.75M |
| Low Forecast | $61.02M | $59.58M | $57.89M | $56.83M | $55.91M | $48.86M | $45.51M | $12.67M | $46.21M | $41.39M | $43.31M | $11.52M | $-57.50M | $21.11M | $20.55M | $10.47M | $13.83M | $14.43M | $14.36M | $19.47M | $13.14M | $13.14M | $12.63M | $22.40M | $12.45M | $12.63M | $12.87M | $-5.31M | $11.42M | $-32.62M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.04% | 0.81% | 4.56% | -0.27% | 2.77% | 2.40% | 0.74% | -2.14% | 2.18% | 2.34% | 1.58% | 2.44% | 2.79% | 2.66% | 0.56% | 0.15% | -0.16% | -0.05% | 1.26% | 1.20% | 0.84% |
3 analysts predict COLL's average Quarter EBITDA for Dec 23 to be $46.76M, with a high of $47.03M and a low of $46.21M. This is 3.87% upper than Collegium Pharmaceutical's previous annual EBITDA (Sep 23) of $45.01M.
Collegium Pharmaceutical Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 1 | 3 | 6 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 12 | 15 |
| Net Income | - | - | - | - | - | - | - | - | - | $20.63M | $13.01M | $-17.43M | $-7.20M | $457.00K | $-5.19M | $-13.07M | $-25.03M | $8.05M | $72.84M | $15.66M | $6.96M | $11.29M | $8.06M | $450.00K | $-2.41M | $-5.84M | $-4.71M | $-9.41M | $-18.65M | $-22.88M |
| Avg Forecast | $70.55M | $68.94M | $64.91M | $62.97M | $60.45M | $63.92M | $59.65M | $-21.51M | $55.36M | $48.93M | $48.92M | $-19.55M | $-70.98M | $55.80M | $58.15M | $-17.77M | $42.07M | $38.77M | $38.88M | $9.92M | $39.00M | $36.29M | $34.67M | $799.05K | $2.02M | $2.13M | $-1.82M | $-7.68M | $-15.61M | $-27.55M |
| High Forecast | $71.67M | $70.02M | $65.94M | $67.91M | $65.25M | $65.52M | $59.65M | $-17.21M | $61.60M | $56.45M | $49.44M | $-15.64M | $-56.78M | $58.02M | $58.15M | $-14.22M | $42.07M | $38.77M | $39.86M | $11.90M | $39.00M | $36.29M | $34.67M | $958.86K | $2.02M | $2.13M | $-1.82M | $-6.14M | $-12.49M | $-22.04M |
| Low Forecast | $69.56M | $67.97M | $64.00M | $58.03M | $56.44M | $62.32M | $59.64M | $-25.81M | $47.87M | $44.22M | $48.40M | $-23.46M | $-85.17M | $53.58M | $58.15M | $-21.33M | $42.07M | $38.77M | $37.91M | $7.94M | $39.00M | $36.29M | $34.67M | $639.24K | $2.02M | $2.13M | $-1.82M | $-9.21M | $-18.73M | $-33.06M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.42% | 0.27% | 0.89% | 0.10% | 0.01% | -0.09% | 0.74% | -0.60% | 0.21% | 1.87% | 1.58% | 0.18% | 0.31% | 0.23% | 0.56% | -1.19% | -2.74% | 2.59% | 1.23% | 1.20% | 0.83% |
Collegium Pharmaceutical's average Quarter net income forecast for Dec 23 is $55.36M, with a range of $47.87M to $61.60M. COLL's average Quarter net income forecast represents a 168.29% increase compared to the company's last Quarter net income of $20.63M (Sep 23).
Collegium Pharmaceutical SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 1 | 3 | 6 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 12 | 15 |
| SG&A | - | - | - | - | - | - | - | - | - | $35.30M | $38.19M | $52.77M | $38.03M | $38.37M | $41.25M | $54.53M | $26.60M | $30.51M | $30.37M | $31.48M | $26.82M | $26.43M | $29.32M | $31.26M | $25.09M | $30.07M | $28.93M | $32.35M | $31.58M | $22.85M |
| Avg Forecast | $71.84M | $70.15M | $68.15M | $66.81M | $66.10M | $57.32M | $53.01M | $89.73M | $54.45M | $50.55M | $50.99M | $81.57M | $75.42M | $45.81M | $44.61M | $74.16M | $30.03M | $31.33M | $31.16M | $19.93M | $28.51M | $28.52M | $27.41M | $55.51M | $27.02M | $27.41M | $27.93M | $25.61M | $26.43M | $992.27K |
| High Forecast | $72.71M | $71.00M | $68.98M | $67.44M | $67.05M | $57.74M | $53.01M | $107.68M | $54.78M | $52.06M | $51.61M | $97.89M | $90.51M | $45.81M | $44.61M | $88.99M | $30.03M | $31.33M | $31.16M | $23.92M | $28.51M | $28.52M | $27.41M | $66.61M | $27.02M | $27.41M | $27.93M | $30.73M | $31.71M | $1.19M |
| Low Forecast | $71.06M | $69.39M | $67.42M | $66.19M | $65.12M | $56.91M | $53.01M | $71.79M | $53.82M | $48.20M | $50.44M | $65.26M | $60.34M | $45.81M | $44.61M | $59.33M | $30.03M | $31.33M | $31.16M | $15.95M | $28.51M | $28.52M | $27.41M | $44.41M | $27.02M | $27.41M | $27.93M | $20.49M | $21.14M | $793.82K |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.70% | 0.75% | 0.65% | 0.50% | 0.84% | 0.92% | 0.74% | 0.89% | 0.97% | 0.97% | 1.58% | 0.94% | 0.93% | 1.07% | 0.56% | 0.93% | 1.10% | 1.04% | 1.26% | 1.20% | 23.02% |
Collegium Pharmaceutical's average Quarter SG&A projection for Dec 23 is $54.45M, based on 3 Wall Street analysts, with a range of $53.82M to $54.78M. The forecast indicates a 54.27% rise compared to COLL last annual SG&A of $35.30M (Sep 23).
Collegium Pharmaceutical EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 1 | 3 | 6 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 12 | 15 |
| EPS | - | - | - | - | - | - | - | - | - | $0.61 | $0.38 | $-0.51 | $-0.21 | $0.01 | $-0.15 | $-0.39 | $-0.73 | $0.23 | $2.06 | $0.45 | $0.20 | $0.33 | $0.23 | $-0.12 | $-0.07 | $-0.17 | $-0.13 | $-0.28 | $-0.74 | $-0.78 |
| Avg Forecast | $1.76 | $1.72 | $1.62 | $1.57 | $1.50 | $1.59 | $1.49 | $1.47 | $1.38 | $1.22 | $1.22 | $1.33 | $1.09 | $1.38 | $1.44 | $0.90 | $1.04 | $0.96 | $0.96 | $1.00 | $0.97 | $0.90 | $0.86 | $0.66 | $0.05 | $0.05 | $-0.04 | $-0.15 | $-0.41 | $-1.17 |
| High Forecast | $1.78 | $1.74 | $1.64 | $1.69 | $1.62 | $1.63 | $1.49 | $1.52 | $1.53 | $1.41 | $1.23 | $1.38 | $1.11 | $1.44 | $1.44 | $0.90 | $1.04 | $0.96 | $0.99 | $1.00 | $0.97 | $0.90 | $0.86 | $0.66 | $0.05 | $0.05 | $-0.04 | $-0.15 | $-0.33 | $-0.94 |
| Low Forecast | $1.73 | $1.69 | $1.59 | $1.44 | $1.41 | $1.55 | $1.49 | $1.42 | $1.19 | $1.10 | $1.21 | $1.28 | $1.08 | $1.33 | $1.44 | $0.90 | $1.04 | $0.96 | $0.94 | $1.00 | $0.97 | $0.90 | $0.86 | $0.66 | $0.05 | $0.05 | $-0.04 | $-0.15 | $-0.49 | $-1.40 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.50% | 0.31% | -0.38% | -0.19% | 0.01% | -0.10% | -0.44% | -0.70% | 0.24% | 2.14% | 0.45% | 0.21% | 0.37% | 0.27% | -0.18% | -1.44% | -3.22% | 2.89% | 1.90% | 1.80% | 0.67% |
According to 3 Wall Street analysts, Collegium Pharmaceutical's projected average Quarter EPS for Dec 23 is $1.38, with a low estimate of $1.19 and a high estimate of $1.53. This represents a 125.96% increase compared to COLL previous annual EPS of $0.61 (Sep 23).
Collegium Pharmaceutical Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PROC | Procaps Group | $3.69 | $10.00 | 171.00% | |
| EOLS | Evolus | $11.73 | $24.00 | 104.60% | Buy |
| AMPH | Amphastar Pharmaceuticals | $40.85 | $66.00 | 61.57% | Buy |
| ANIP | ANI Pharmaceuticals | $55.83 | $79.00 | 41.50% | Buy |
| COLL | Collegium Pharmaceutical | $30.90 | $42.33 | 36.99% | Buy |
| ALKS | Alkermes | $30.75 | $37.50 | 21.95% | Hold |
| PCRX | Pacira BioSciences | $19.83 | $23.75 | 19.77% | Hold |
| PBH | Prestige Consumer Healthcare | $80.39 | $89.50 | 11.33% | Buy |
| ITCI | Intra-Cellular Therapies | $86.96 | $93.33 | 7.33% | Buy |
| PAHC | Phibro Animal Health | $22.34 | $18.67 | -16.43% | Buy |